Contralateral non-auditory stimulation in auditory brainstem implantation: A case report

Batuk, Merve Ozbal; Aslan, Filiz; Sennaroğlu, Gonca; Akgöz, Ayça; Bilginer, Burçak; Sennaroḡlu, Levent

doi:10.1016/j.ijporl.2019.06.026

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…Recently, a long term follow‐up study of 30 pediatric ABI patients found that children who received an ABI before age 3 performed better on auditory perception testing and had higher speech intelligibility scores as compared to children implanted over 3 years of age 16 . The largest study to date examining bimodal stimulation was done in 12 pediatric patients with CI and contralateral ABI for pontocerebellar hypoplasia, and found that auditory perception scores, MAIS scores, pattern perception, and word recognition scores were all significantly higher than CI‐only or ABI‐only conditions in these patients 17 …”

Section: Resultsmentioning

confidence: 99%

“…16 The largest study to date examining bimodal stimulation was done in 12 pediatric patients with CI and contralateral ABI for pontocerebellar hypoplasia, and found that auditory perception scores, MAIS scores, pattern perception, and word recognition scores were all significantly higher than CI-only or ABI-only conditions in these patients. 17 In the past, there had been few studies examining the growth and subsequent language development of pediatric ABI patients. Excitingly, recent literature has shown improvements in both nonverbal communication and oral language development following ABI implantation.…”

Section: Abi Clinical Outcomes E Non-nf2 Pediatric Indicationsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and scientific innovations in auditory brainstem implants

Shetty

Ridge

Kanumuri

et al. 2021

World j. otorhinolaryngol.-head neck surg.

View full text Add to dashboard Cite

The auditory brainstem implant (ABI) was originally developed to provide rehabilitation of retrocochlear deafness caused by neurofibromatosis type 2 (NF2). Recent studies of the ABI have investigated outcomes in non-NF2 cohorts, such as patients with cochlear nerve aplasia or cochlear ossification and more recently, intractable tinnitus. New technologies that improve the ABI-neural tissue interface are being explored as means to improve performance and decrease side effects. Innovative discoveries in optogenetics and bioengineering present opportunities to continually evolve this technology into the future, enhancing spatial selectivity of neuronal activation in the cochlear nucleus and preventing side effects through reduction in activation of non-target neuronal circuitry. These advances will improve surgical planning and ultimately improve patients’ audiological capabilities. ABI research has rapidly increased in the 21st century and applications of this technology are likely to continually evolve. Herein, we aim to characterize ongoing clinical, basic science, and bioengineering advances in ABIs and discuss future directions of this technology.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%